BMO Capital Markets downgraded BioNTech to market perform, citing a failed Phase 2 clinical trial and lowered revenue guidance, though the company maintains a robust pipeline of over 25 late-stage oncology studies.
The stock was downgraded by BMO Capital Markets and the company canceled a key Phase 2 clinical trial while lowering full-year revenue guidance.
Mentioned only as a peer with positive late-stage results that previously boosted sector sentiment but is not the primary focus of the article's analysis.
Mentioned as a partner in a successful mRNA cancer vaccine study, serving as a contextual benchmark for BioNTech's pipeline rather than a direct subject of the downgrade.
BioNTech shares faced downward pressure after BMO Capital Markets downgraded the stock from outperform to market perform, slashing its price target from $128 to $105. The move follows the company's decision to cancel a Phase 2 colorectal cancer vaccine trial and a subsequent reduction in full-year revenue guidance to a range of €1.6 billion to €1.9 billion.
The downgrade was driven by a combination of waning COVID-19 vaccine demand, the cancellation of a Phase 2 colorectal cancer vaccine trial, and a downward revision of the company's full-year revenue guidance.
Yes, the company continues to advance a broad oncology pipeline with over 25 Phase 2 and 3 studies, including recent positive data for gotistobart in non-small cell lung cancer.